Akari Therapeutics PLC (AKTX)

[mick]

$AKTX ]fast track approval Open pivotal study in pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) with orphan and fast track approval

Preparing for pivotal study in bullous pemphigoid (BP) following recent

completion of successful Phase II study

Positive EMA opinion on orphan designation for nomacopan for BP along with

Orphan Drug designation granted by FDA in BP


https://finance.yahoo.com/news/akari-therapeutics-reports-first-quarter-110010702.html